Key result
Age ≥80 years was an independent risk factor for bleeding events (OR 5.188) in patients receiving fondaparinux for VTE prophylaxis after colorectal cancer surgery.
Why the study?
What are the risk factors for bleeding in patients receiving fondaparinux for VTE prophylaxis after colorectal cancer surgery?
Cohort (n=546)
No
What are the risk factors for bleeding in patients receiving fondaparinux for VTE prophylaxis after colorectal cancer surgery?
Age ≥80 years is an independent risk factor for bleeding in patients receiving fondaparinux for VTE prophylaxis after colorectal cancer surgery.
Requires caution with fondaparinux VTE prophylaxis in patients ≥80 years after colorectal cancer surgery; leaves open age-stratified regimen trials.
Objective: The aim of this study was to identify risk factors for bleeding complications in patients who receive Venous thromboembolism (VTE) prophylaxis with fondaparinux (FPX) after colorectal cancer surgery. Methods: Records of 546 patients who underwent VTE prophylaxis with intermittent pneumatic compression and FPX after colorectal cancer surgery between January 2009 and May 2014 were reviewed. Patient characteristics, surgical procedures, and patient laboratory data were examined to identify risk factors for bleeding complications using univariate and multivariate logistic regression. Results: We reviewed the records of 324 males and 222 females. Median age and BMI were 68.5 years and 22.7 kg/m2, respectively. The number of laparoscopic surgeries was 366. Median operative time and blood loss were 188.5 min and 20 ml, respectively. The incidence (%) of bleeding events was 5.3%. In univariate analysis, age ≥80 years, BMI ≥25.0 kg/m2, hypertension, and antithrombotic therapy were associated with a significantly higher incidence of bleeding events. Multivariate analysis identified age ≥80 years (odds ratio 5.814; 95% confidence interval 2.502-13.278) as an independent risk factor. Conclusion: Age ≥80 is a risk factor for bleeding in patients who receive FPX for VTE prophylaxis after colorectal cancer surgery.
No takes yet. Share an insight, caveat, or question.
Pak et al. (2017) conducted a cohort in Colorectal cancer (n=546). Age ≥80 years vs. Age <80 years was evaluated on Bleeding events (major and minor) (OR 5.188, 95% CI 2.226-11.814, p=0.002). Age ≥80 years was an independent risk factor for bleeding events (OR 5.188) in patients receiving fondaparinux for VTE prophylaxis after colorectal cancer surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Journal of the Anus Rectum and Colon